CSL Behring recently announced that they are discontinuing Mononine®, the company’s human plasma-derived factor therapy indicated for the prevention and control of bleeding in patients with hemophilia B. They noted the modest number of patients using the product and the availability of newer, next generation therapies as the primary impetus for discontinuing the long running treatment – Mononine® has been on the market since 1992. CSL anticipates that current supplies will last until at least mid-2021.
According to a statement released to advocacy organizations, the company is notifying customers of the discontinuation with “ample lead-in time” so that healthcare providers and their patients have adequate time to select a new treatment. CSL has also made available their medical information call center for questions, which can be accessed at 1.800.504.5434, Monday-Friday, 9am-5pm ET.
Source: CSL Behring
